Nanjing Hicin Pharmaceutical Co Ltd (300584) — Working Capital to Net Assets Ratio
Nanjing Hicin Pharmaceutical Co Ltd (300584) has a Working Capital to Net Assets ratio of 2.1% as of March 2026. Working capital of CN¥23.95 Million (current assets of CN¥383.74 Million minus current liabilities of CN¥359.80 Million) is measured against net assets of CN¥1.12 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Nanjing Hicin Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Nanjing Hicin Pharmaceutical Co Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Nanjing Hicin Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 2.1%, reflecting working capital of CN¥23.95 Million against net assets of CN¥1.12 Billion CNY. Check tangible equity quality of Nanjing Hicin Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Nanjing Hicin Pharmaceutical Co Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Nanjing Hicin Pharmaceutical Co Ltd from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Nanjing Hicin Pharmaceutical Co Ltd market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 1.4% | CN¥15.38 Million | CN¥1.10 Billion | CN¥384.32 Million | CN¥368.94 Million | ▼ -0.7 pp |
| 2024 | 2.1% | CN¥21.80 Million | CN¥1.04 Billion | CN¥357.15 Million | CN¥335.35 Million | ▲ +4.4 pp |
| 2023 | -2.3% | CN¥-22.97 Million | CN¥987.50 Million | CN¥377.30 Million | CN¥400.27 Million | ▼ -8.8 pp |
| 2022 | 6.5% | CN¥61.33 Million | CN¥950.57 Million | CN¥378.38 Million | CN¥317.05 Million | ▲ +6.4 pp |
| 2021 | 0.1% | CN¥530.04K | CN¥948.48 Million | CN¥301.96 Million | CN¥301.43 Million | ▼ -16.6 pp |
| 2020 | 16.6% | CN¥112.77 Million | CN¥678.97 Million | CN¥293.74 Million | CN¥180.97 Million | ▼ -4.4 pp |
| 2019 | 21.0% | CN¥137.53 Million | CN¥653.98 Million | CN¥343.17 Million | CN¥205.63 Million | ▼ -0.2 pp |
| 2018 | 21.2% | CN¥123.08 Million | CN¥580.93 Million | CN¥282.69 Million | CN¥159.61 Million | ▼ -19.4 pp |
| 2017 | 40.6% | CN¥210.09 Million | CN¥517.68 Million | CN¥315.09 Million | CN¥105.00 Million | ▲ +31.0 pp |
| 2016 | 9.6% | CN¥26.44 Million | CN¥276.11 Million | CN¥111.49 Million | CN¥85.05 Million | ▼ -3.4 pp |
| 2015 | 12.9% | CN¥30.42 Million | CN¥235.08 Million | CN¥108.36 Million | CN¥77.94 Million | ▲ +4.3 pp |
| 2014 | 8.6% | CN¥17.24 Million | CN¥200.15 Million | CN¥100.26 Million | CN¥83.02 Million | ▼ -4.5 pp |
| 2013 | 13.1% | CN¥21.68 Million | CN¥165.93 Million | CN¥86.56 Million | CN¥64.88 Million | ▼ -13.2 pp |
| 2012 | 26.3% | CN¥34.89 Million | CN¥132.65 Million | CN¥81.81 Million | CN¥46.92 Million | — |